• UCLA Health
  • myUCLAhealth
  • School of Medicine
Institute of Urologic Oncology

UCLA Institute of Urologic Oncology

Institute of Urologic Oncology
  • About Us
    • Director's Welcome
    • Board of Directors
    • IUO in the News
    • Why Choose the UCLA IUO
    • Support the IUO
    • Contact Us
    • The Wasserman Building
    • Maps and Directions
    • IUO Membership Information
    • Administrative & Research Staff
    • Positions Available
  • Clinical Programs
    • Bladder Cancer
    • Kidney Cancer
    • Prostate Cancer
    • Testicular Cancer
    • Integrated Cancer Program
    • Cancer Genetic Risk Assessment Program
    • Second Opinion for Cancer
  • Research Programs
    • Clinical Trials
    • Faculty Labs
    • Bladder Cancer
    • Kidney Cancer
    • Prostate Cancer
    • LuPSMA Risk Calculator
    • PSMA Risk Calculator
    • SPORE In Prostate Cancer
    • Webinars / Videos
  • Clinical Trials
    • What Is a Clinical Trial?
    • Who Should Consider Clinical Trials & Why
    • Bladder Cancer Clinical Trials
    • Kidney Cancer Clinical Trials
    • Prostate Cancer Clinical Trials
    • Testicular Cancer Clinical Trials
    • Clinical Research Team
    • IUO Membership Study Information
  • For Patients
    • Contact Us
    • Clinical Updates
    • Maps and Directions
    • myUCLAhealth
    • Webinars / Videos
  • Fellowship
    • Current Fellows
    • Former Fellows
    • Fellow Testimonials
    • UCLA Health Aerial Tour
    • Webinars/Videos
  • For Healthcare Professionals
    • How to Refer a Patient
    • Lectures & Conferences
    • CTSI Distinguished Speaker Seminar Series
    • DGSOM Research Seminars
    • DGSOM Events
    • JCCC Seminars
    • Researcher Resources
    • SPORE Lectures
  • Expert Team
    • Board of Directors
    • Medical Oncology
    • Nuclear Medicine
    • Pathology
    • Radiation Oncology
    • Radiology
    • Urologic Oncology
    • Research Faculty
    • Emeritus Faculty
  • UCLA Health
  • myUCLAhealth
  • School of Medicine

UCLA Institute of Urologic Oncology

Research Programs

Research Programs

Research Programs

  • Clinical Trials
  • Faculty Labs
    • Dr. Corey Arnold Lab
      • Meet Our Team
      • Publications
    • Dr. Paul Boutros Lab
      • Research Areas
      • Meet Our Team
      • Publications
    • Dr. Jeremie Calais Lab
      • Research Areas
      • Meet Our Team
      • Publications
      • Videos
    • Dr. Karim Chamie Lab
      • Meet Our Team
      • Publications
    • Dr. Andrew Goldstein Lab
      • Research Areas
      • Meet Our Team
      • Publications
    • Dr. William Hsu Lab
      • Meet Our Team
      • Publications
    • Dr. Amar Kishan Research
      • Meet Our Team
      • Publications
    • Drs. Lueckerath/Mona Lab
      • Meet Our Team
      • Publications
    • Dr. Leonard S Marks Lab
      • Meet Our Team
      • Publications
    • Dr. Robert Reiter Lab
      • Meet Our Team
      • Publications
    • Dr. Lily Wu Lab
      • Meet Our Team
      • Publications
  • Bladder Cancer
  • Kidney Cancer
    • Unique Tumor Repository Launched
  • Prostate Cancer
  • LuPSMA Risk Calculator
  • PSMA Risk Calculator
  • SPORE In Prostate Cancer
  • Webinars / Videos
  • Clinical Trials
  • Faculty Labs
  • Bladder Cancer
  • Kidney Cancer
  • Prostate Cancer
  • LuPSMA Risk Calculator
  • PSMA Risk Calculator
  • SPORE In Prostate Cancer
  • Webinars / Videos
  • Dr. Corey Arnold Lab
  • Dr. Paul Boutros Lab
  • Dr. Jeremie Calais Lab
  • Dr. Karim Chamie Lab
  • Dr. Andrew Goldstein Lab
  • Dr. William Hsu Lab
  • Dr. Amar Kishan Research
  • Drs. Lueckerath/Mona Lab
  • Dr. Leonard S Marks Lab
  • Dr. Robert Reiter Lab
  • Dr. Lily Wu Lab
  • Research Areas
  • Meet Our Team
  • Publications
  1. Home
  2. Institute of Urologic Oncology
  3. Research Programs
  4. Faculty Labs
  5. Dr. Andrew Goldstein Lab
  6. Research Areas

Research Areas

Share this

Recent Research

Progenitor Cells and CancerLarger image >

Aging and CancerLarger image >

Progenitor Cells and Cancer

Cancer is believed to develop from an accumulation of genetic alterations in normal cells that confer an advantage such as increased oncogenic signaling or loss of tumor suppressors. The cells that acquire these genetic alterations and go on to initiate cancer are termed the cells-of-origin for cancer. Whether there are particular cells in adult tissues that are more likely to develop into cancer in response to genetic alterations has been a question of debate in recent decades. We and others have utilized approaches to distinguish progenitor cells (which can replicate and generate new cells) from differentiated cells and demonstrated that progenitor cells can more easily initiate cancer following the introduction of genetic alterations. As tumors progress and develop resistance to current therapies, tumor cells tend to change their appearance and the genes they turn on or off in order to evade treatments, a process that results in cancer cells more closely resembling progenitor cells. Understanding tumor cell adaptability, and investigating how cancer cells acquire progenitor properties, is important for combating treatment-resistance cancer.

Aging and Cancer

Aging is associated with an accumulation of somatic mutations and epigenetic changes in normal cells. Many cancers are considered diseases of aging. Age is a significant risk factor for prostate cancer, but the mechanisms by which age increases disease risk is poorly understood. Chronic inflammation is associated with aging in many tissues and chronic inflammation is also a risk factor for many age-related cancers including prostate cancer. Mass cytometry has emerged as a tool to interrogate immune populations in dissociated preparations of tissues, and we have utilized mass cytometry for immune profiling in mouse and human prostates. We have demonstrated that luminal progenitor cells are expanded both in prostate tissue with chronic inflammation and in aging prostate tissue. Increasing the number of progenitor cells at risk for transformation likely increases the risk for disease initiation. Understanding how aging alters prostatic inflammation and progenitor content is essential for determining how to prevent or reverse the effects of aging and reduce disease risk.

Metabolism and Cancer

As transformed cells develop into cancer, and cancer cells develop resistance to therapy, their energetic demands change. As tumor cells adapt to a changing environment, the fuels they utilize can also change. Metabolic reprogramming during tumor initiation, progression and treatment-resistance regulates cell survival, proliferation and gene expression. We have found that CD38, a molecule which is highly expressed in prostate luminal cells but absent in aggressive prostate cancer, regulates extracellular NAD+. Determining how cellular metabolism enables tumor cell plasticity is critical for designing effective therapeutic approaches for lethal cancer.

Like Us on Facebook Follow Us on Twitter Subscribe to Our Videos on YouTube Follow us on Instagram Connect with Us on LinkedIn Follow us on Pinterest
UCLA Health hospitals ranked best hospitals by U.S. News & World Report
  • UCLA Health
  • Find a Doctor
  • School of Medicine
  • School of Nursing
  • UCLA Campus
  • Directory
  • Newsroom
  • Subscribe
  • Patient Stories
  • Giving
  • Careers
  • Volunteer
  • International Services
  • Privacy Practices
  • Nondiscrimination
  • Billing
  • Health Plans
  • Emergency
  • Report Broken Links
  • Terms of Use
  • 1-310-825-2631
  • Maps & Directions
  • Contact Us
  • Your Feedback
  • Report Misconduct
  • Get Social
  • Sitemap
Like Us on Facebook Follow Us on Twitter Subscribe to Our Videos on YouTube Follow us on Instagram Connect with Us on LinkedIn Follow us on Pinterest